Learn about our expanded patient care options and visitor guidelines.
General Information | Self-Checker | Donate and Lend Support | Staff Appreciation | Get Email Alerts
Enter the last name, specialty or keyword for your search below.
Work in the Christian Merlo Lab includes studies on pulmonary arteriovenous malformations, outcomes in lung transplantation and treatment of cystic fibrosis (CF), and HIV-related pulmonary disease. We have studied methods of diagnosing and managing pulmonary arteriovenous malformations as well as the outcomes of adult CF patients who are infected with multiple antibiotic-resistant Pseudomonas aeruginosa. Our recent research has also explored recipient and donor variables in the success or failure of lung transplants, and ways in which national healthcare delivery systems impact lung transplant outcomes for CF patients.
Work in the Kristin Riekert Lab focuses on methods for improving health care quality and delivery, particularly among underserved and disadvantaged populations. Our research covers a range of important topics, including health beliefs, treatment adherence, doctor-patient communication, self-management interventions, mobile health initiatives, health disparities and patient-reported outcome methodology. We also work with the National Institutes of Health on multiple intervention trials focused on improving adherence and health outcomes in asthma, chronic kidney disease, cystic fibrosis (CF), sickle cell disease and secondhand smoke reduction.
Research in the Liudmila Cebotaru Lab studies cystic fibrosis transmembrane conductance regulator (CFTR) mutants. We also investigate corrector molecules that are currently in clinical trials to get a better understanding of their mechanism of action. A major focus of our research is on developing more efficient gene therapy vectors with the ultimate goal of developing a gene therapy for cystic fibrosis.
The Mark Jennings Lab conducts research on bacterial infection in patients with cystic fibrosis. We are currently conducting a clinical trial to investigate the epidemiology and treatment of small-colony variant staphylococcus aureus in cystic fibrosis. We’ve also recently studied eradication strategies for persistent methicillin-resistant staphylococcus aureus infection in patients with cystic fibrosis.
The Michelle Eakin Lab conducts research on behavioral science and adherence and asthma outcomes in inner-city children. Our studies into behavioral science have included exploring the impact of medication adherence on lung health outcomes in patients with cystic fibrosis, disparities in anti-hypertensive medication adherence in adolescents and other key topics. We also investigate methods for improving asthma care and treatment as well as health disparities among various ethnicities, particularly in pediatric patients.
The Natalie West Lab collaborates with Noah Lechtzin’s lab to study cystic fibrosis, with a particular focus on new resistant bacteria and their effect on the lung function of people with cystic fibrosis.
Research in the Noah Lechtzin Lab investigates several important aspects of cystic fibrosis (CF), including the impact of antibiotic-resistant bacterial infections in CF patients and new therapy options for individuals with CF. Our research into new CF therapies has included studies on home electronic symptom and lung function monitoring, transbronchial needle aspiration and bedside percutaneous endoscopic gastrostomy tube placement. We also explore the role of metabolic complications in CF patients by examining how the disease is impacted by factors such as vitamin D deficiency, osteoporosis and testosterone deficiency.
Work in the William B. Guggino Lab focuses on the structure of the cystic fibrosis transmembrane conductance regulator (CFTR) and water channels; the molecular structure of transport proteins in epithelial cell membranes; and gene therapies to treat cystic fibrosis (CF) patients. We are also working to identify CF’s specific defect in chloride channel regulation. One recent study showed that insulin-like growth factor 1 (IGF-1) enhances the protein expression of CFTR.
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
